| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
JAK3; S-enantiomer of Tofacitinib, less active
The primary targets of (3S,4S)-Tofacitinib are the Janus kinase (JAK) enzymes, which are key components of the JAK-STAT signaling pathway. However, it is the less active enantiomer of tofacitinib, meaning it has significantly lower inhibitory activity against JAKs compared to the active (3R,4R)-enantiomer. The compound's reduced activity makes it a valuable reference standard for chiral purity analysis and for studying the stereospecificity of JAK inhibition. |
|---|---|
| ln Vitro |
(3S,4S)-Tofacitinib is an impurity and the diasteromer of Tofacitinib, and is less active than Tofacitinib.
In vitro, (3S,4S)-Tofacitinib is significantly less active than its (3R,4R)-enantiomer as a JAK inhibitor. While specific IC50 values for JAK inhibition are not extensively reported, the compound's reduced activity is well-established in the literature. Its primary in vitro application is as a reference standard in analytical method development for tofacitinib and its related substances, particularly for chiral purity analysis. The compound is used in method validation (AMV) and quality control (QC) applications. |
| ln Vivo |
In vivo data for (3S,4S)-Tofacitinib are not extensively reported. As the less active enantiomer of tofacitinib, it is not expected to have significant pharmacological activity in vivo. Its primary use is as a reference standard and research tool, rather than as a therapeutic agent. The compound is not intended for in vivo pharmacological studies.
|
| Enzyme Assay |
In vitro enzyme assays for (3S,4S)-Tofacitinib typically involve measuring its inhibitory activity against JAK enzymes, comparing its potency to the active (3R,4R)-enantiomer. Recombinant JAK enzymes are incubated with peptide substrates and ATP in the presence of varying concentrations of the compound. The phosphorylation of the substrate is measured, and the IC50 for inhibition is calculated. However, specific IC50 values for the (3S,4S)-enantiomer are not detailed in the available literature.
|
| Cell Assay |
In vitro cellular assays for (3S,4S)-Tofacitinib are not typically performed, as the compound is not used as an active pharmacological agent. Its primary application is in analytical chemistry rather than cell-based pharmacology. However, in research settings, the compound may be used as a control in cellular assays to demonstrate the stereospecificity of JAK inhibition or to validate analytical methods.
|
| Animal Protocol |
In vivo animal studies with (3S,4S)-Tofacitinib are not typically performed, as the compound is not a therapeutic agent. Its use is limited to analytical method development and quality control applications for tofacitinib formulations. The compound is not intended for in vivo pharmacological or toxicological studies.
|
| ADME/Pharmacokinetics |
(3S,4S)-Tofacitinib has a molecular weight of 312.37 and is soluble in DMSO at ≥100 mg/mL. It is stable as a powder when stored at -20°C for up to 3 years and in solution at -80°C for up to 1 year. However, detailed pharmacokinetic parameters are not applicable for this compound, as it is not used as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for (3S,4S)-Tofacitinib are not extensively reported. As the less active enantiomer of tofacitinib, it is expected to have a different toxicological profile, but specific data are not available. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/20111936
|
| Additional Infomation |
(3S,4S)-Tofacitinib is a research-grade compound and the less active enantiomer of the FDA-approved drug tofacitinib. It is not approved for clinical use. Its primary applications are in analytical method development, method validation (AMV), and quality controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of tofacitinib. It is also used as a reference standard for chiral purity analysis of tofacitinib formulations.
|
| Molecular Formula |
C16H20N6O
|
|---|---|
| Molecular Weight |
312.3696
|
| Exact Mass |
312.17
|
| Elemental Analysis |
C, 61.52; H, 6.45; N, 26.90; O, 5.12
|
| CAS # |
1092578-47-6
|
| Related CAS # |
Tofacitinib;477600-75-2;Tofacitinib citrate;540737-29-9;(3R,4S)-Tofacitinib;1092578-46-5;(3S,4R)-Tofacitinib;1092578-48-7
|
| PubChem CID |
20111936
|
| Appearance |
Off-white to pink solid powder
|
| LogP |
1.482
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
488
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H]1CCN(C[C@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
|
| InChi Key |
UJLAWZDWDVHWOW-WCQYABFASA-N
|
| InChi Code |
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m0/s1
|
| Chemical Name |
3-[(3S,4S)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
|
| Synonyms |
(3S,4S)-Tofacitinib; 1092578-47-6; 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; (-)-Tofacitinib; C3EP7ZZ9UQ; Tofacitinib, (3S,4S)-; CHEMBL459769; 3-[(3S,4S)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~320.13 mM)
H2O : ~0.67 mg/mL (~2.14 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2013 mL | 16.0067 mL | 32.0133 mL | |
| 5 mM | 0.6403 mL | 3.2013 mL | 6.4027 mL | |
| 10 mM | 0.3201 mL | 1.6007 mL | 3.2013 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
